PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT

Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71982-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)71982-9/fulltext
Title : PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71982-9&doi=10.1016/S1098-3015(11)71982-9
First page : A267
Section Title : RESEARCH POSTER ABSTRACTS
Open access? : No
Section Order : 140
Categories :
Tags :
Regions :
ViH Article Tags :